Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Announces Additional Job Cuts as Part of Restructuring

NEW YORK (GenomeWeb) – Interpace Diagnostics announced today that it has cut 18 employees as part of an ongoing effort to restructure itself into a pure-play molecular diagnostics firm.

The move, the company said, will result in about $11.5 million in annual cost savings. 

In November, Interpace — formerly known as PDI — disclosed that it was selling off its biomedical commercialization and marketing services business in order to focus on its molecular diagnostic offerings, which include the ThyGenX genetic mutation panel and its soon-to-be-launched ThyraMir microRNA expression classifier. A month later, the firm trimmed 36 staffers, primarily from its commercial services segment. 

Interpace said today it has since eliminated the additional positions, while realigning its compensation structure, consolidating job roles, eliminating certain R&D programs, and streamlining its operating systems.

"The transition process from being a combined contract sales and molecular diagnostics business to a standalone, fully integrated molecular diagnostics company is nearly complete," Interim President and CEO Jack Stover said in a statement "Our job now is to begin delivering consistent growth in our core molecular diagnostics business that we are confident is possible while continuing to focus on controlling costs."

During early morning trading on the Nasdaq, shares of Interpace were down 6 percent at $.23.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.